What are the ozanimod studies?

Induction 1 (RPC01-3201) and Induction 2 (RPC01-3202) are phase 3, randomized, double-blind, placebo-controlled, multicenter trials that will investigate the efficacy and safety of ozanimod, an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.

The primary objective of each study is to evaluate the efficacy of oral ozanimod compared with placebo in subjects with moderately to severely active Crohn’s disease after 12 weeks of treatment.

Induction 1 and 2 are currently enrolling patients.

Yellowstone induction 1 study
Yellowstone induction 2 study